BiotechTube
Simphotek

Simphotek

Newark, United States· Est.
simphotek.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $375K

Overview

Simphotek, founded in 2006, is a private biotechnology company pioneering computational medical devices for Photodynamic Therapy (PDT). Its platform, centered on the Dosie™ treatment planning system and the underlying SimphoSOFT® simulation software, is designed to make PDT more precise, effective, and accessible for treating advanced cancers. With strong academic partnerships, government grant funding, and a focus on cancers with high unmet need, Simphotek is advancing a first-in-class platform to establish PDT as a standard-of-care alternative to conventional therapies.

Oncology

Technology Platform

Patented simulation software (SimphoSOFT®) and integrated computational medical device (Dosie™) for real-time dosimetry and treatment planning in Photodynamic Therapy (PDT). The platform models light distribution and photochemical drug toxicity in biological tissues.

Funding History

2
Total raised:$375K
Grant$150K
Grant$225K

Opportunities

The primary opportunity is to establish a new standard of care in PDT by solving the critical dosimetry challenge, enabling broader adoption of this less toxic cancer therapy.
Success in niche, high-need indications like mesothelioma can serve as a springboard to expand the platform across numerous other solid tumor types treated with PDT, creating a large, scalable market.

Risk Factors

Key risks include regulatory hurdles in obtaining FDA clearance for the Dosie™ medical device, the challenge of driving adoption in a clinical community accustomed to existing cancer therapies, and reliance on grant funding which may be insufficient to finance full commercialization.
Execution risk for its small team is also significant.

Competitive Landscape

Simphotek appears first-in-class with its integrated computational dosimetry device for PDT. Direct competitors are likely limited, but it competes indirectly with the empirical standard of care for PDT and with other emerging adjuvant therapies for cancers like mesothelioma. Its main competition is the inertia of existing clinical practice rather than a specific analogous device.

More companies in Oncology (General) →More companies in United States →